Trend of Demographics of Cardiovascular Disease Fellows and Association Between Fellows and Program Director Race

Ankur Kalra; Grant W. Reed; Rishi Puri; Monil Majmundar; Ashish Kumar; Jeff D. Foley; Harshvardhan Zala; Khurram Nasir; Samir R. Kapadia; Deepak L. Bhatt

doi:10.1016/j.jacadv.2022.100032

Trend of Demographics of Cardiovascular Disease Fellows and Association Between Fellows and Program Director Race

Ankur Kalra, Grant W. Reed, Rishi Puri, Monil Majmundar, Ashish Kumar, Jeff D. Foley, Harshvardhan Zala, Khurram Nasir, Samir R. Kapadia, Deepak L. Bhatt

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Original language	English (US)
Article number	100032
Journal	JACC: Advances
Volume	1
Issue number	2
DOIs	https://doi.org/10.1016/j.jacadv.2022.100032
State	Published - Jun 2022

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Dentistry (miscellaneous)

Access to Document

10.1016/j.jacadv.2022.100032

Cite this

@article{984c1a53939a4a789065106cc4d91b31,

title = "Trend of Demographics of Cardiovascular Disease Fellows and Association Between Fellows and Program Director Race",

author = "Ankur Kalra and Reed, {Grant W.} and Rishi Puri and Monil Majmundar and Ashish Kumar and Foley, {Jeff D.} and Harshvardhan Zala and Khurram Nasir and Kapadia, {Samir R.} and Bhatt, {Deepak L.}",

note = "Funding Information: This study received funding from makeadent.org Ram and Sanjita Kalra Aavishqaar Fund. Dr Kalra is the chief executive officer and creative director of makeadent.org. Dr Bhatt discloses the following relationships—advisory board: Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, and Stasys; board of directors: Boston VA Research Institute, DRS.LINQ (stock options), Society of Cardiovascular Patient Care, and Tobesoft; chair: inaugural chair, American Heart Association Quality Oversight Committee; data monitoring committees: Acesion Pharma, Assistance Publique-H{\^o}pitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health Research Institute, and Rutgers University (for the NIH-funded MINT Trial); honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor; associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and US national co-leader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today{\textquoteright}s Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees); and other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair); research funding: Abbott , Afimmune , Aker Biomarine , Amarin , Amgen , AstraZeneca , Bayer , Beren , Boehringer Ingelheim , Bristol Myers Squibb , Cardax , CellProthera , Cereno Scientific , Chiesi , CSL Behring , Eisai , Ethicon , Faraday Pharmaceuticals , Ferring Pharmaceuticals , Forest Laboratories , Fractyl , Garmin , HLS Therapeutics , Idorsia , Ironwood , Ischemix , Janssen , Javelin , Lexicon , Lilly , Medtronic , Moderna , MyoKardia , NirvaMed , Novartis , Novo Nordisk , Owkin , Pfizer , PhaseBio , PLx Pharma , Recardio , Regeneron , Reid Hoffman Foundation , Roche , Sanofi , Stasys , Synaptic , The Medicines Company , and 89Bio ; royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald{\textquoteright}s Heart Disease); site co-investigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, and Svelte; trustee: American College of Cardiology; and unfunded research: FlowCo, Merck, and Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. This material is based upon data provided by the Association of American Medical Colleges (AAMC). The views expressed herein are those of the authors and do not necessarily reflect the position or policy of the AAMC. The authors acknowledge the assistance of Itohan Aikhionbare, Meghana Chanamolu, Sanjana Datla, Sneha Kandi, Vishali Moond, and Bharat Rawlley in data collection. ",

year = "2022",

month = jun,

doi = "10.1016/j.jacadv.2022.100032",

language = "English (US)",

volume = "1",

journal = "JACC: Advances",

issn = "2772-963X",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - Trend of Demographics of Cardiovascular Disease Fellows and Association Between Fellows and Program Director Race

AU - Kalra, Ankur

AU - Reed, Grant W.

AU - Puri, Rishi

AU - Majmundar, Monil

AU - Kumar, Ashish

AU - Foley, Jeff D.

AU - Zala, Harshvardhan

AU - Nasir, Khurram

AU - Kapadia, Samir R.

AU - Bhatt, Deepak L.

N1 - Funding Information: This study received funding from makeadent.org Ram and Sanjita Kalra Aavishqaar Fund. Dr Kalra is the chief executive officer and creative director of makeadent.org. Dr Bhatt discloses the following relationships—advisory board: Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, and Stasys; board of directors: Boston VA Research Institute, DRS.LINQ (stock options), Society of Cardiovascular Patient Care, and Tobesoft; chair: inaugural chair, American Heart Association Quality Oversight Committee; data monitoring committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health Research Institute, and Rutgers University (for the NIH-funded MINT Trial); honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor; associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and US national co-leader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees); and other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair); research funding: Abbott , Afimmune , Aker Biomarine , Amarin , Amgen , AstraZeneca , Bayer , Beren , Boehringer Ingelheim , Bristol Myers Squibb , Cardax , CellProthera , Cereno Scientific , Chiesi , CSL Behring , Eisai , Ethicon , Faraday Pharmaceuticals , Ferring Pharmaceuticals , Forest Laboratories , Fractyl , Garmin , HLS Therapeutics , Idorsia , Ironwood , Ischemix , Janssen , Javelin , Lexicon , Lilly , Medtronic , Moderna , MyoKardia , NirvaMed , Novartis , Novo Nordisk , Owkin , Pfizer , PhaseBio , PLx Pharma , Recardio , Regeneron , Reid Hoffman Foundation , Roche , Sanofi , Stasys , Synaptic , The Medicines Company , and 89Bio ; royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); site co-investigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, and Svelte; trustee: American College of Cardiology; and unfunded research: FlowCo, Merck, and Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. This material is based upon data provided by the Association of American Medical Colleges (AAMC). The views expressed herein are those of the authors and do not necessarily reflect the position or policy of the AAMC. The authors acknowledge the assistance of Itohan Aikhionbare, Meghana Chanamolu, Sanjana Datla, Sneha Kandi, Vishali Moond, and Bharat Rawlley in data collection.

PY - 2022/6

Y1 - 2022/6

UR - http://www.scopus.com/inward/record.url?scp=85144065109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85144065109&partnerID=8YFLogxK

U2 - 10.1016/j.jacadv.2022.100032

DO - 10.1016/j.jacadv.2022.100032

M3 - Article

AN - SCOPUS:85144065109

SN - 2772-963X

VL - 1

JO - JACC: Advances

JF - JACC: Advances

IS - 2

M1 - 100032

ER -

Trend of Demographics of Cardiovascular Disease Fellows and Association Between Fellows and Program Director Race

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this